Children with Ulcerative Colitis May Be Safely Treated with Multimatrix Mesalamine

Children with Ulcerative Colitis May Be Safely Treated with Multimatrix Mesalamine
A study from the Johns Hopkins University School of Medicine reported that children and adolescents with ulcerative colitis (UC) reacted to multimatrix mesalamine treatment in ways similar to adults, with the drug showing a good safety and tolerability profile in all age and dose groups examined. The study, "Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis," was published in the journal Drug Design, Development and Therapy. Multimatrix mesalamine is an oral formulation of 5-aminosalicylic acid (5-ASA) recommended as first-line therapy for adults with active mild to moderate UC. The drug is often used in children with UC as well, but there is little data supporting its efficacy and safety in this population. There is also no 5-ASA product approved for maintenance of remission in children. The Phase 1 clinical trial assessed the properties in the body (pharmacokinetics) of both 5-ASA and its main metabolite, acetyl-5-ASA, in 52 children and adolescents at 12 sites across the United States, Poland, and Slovakia. Participants were ages 5–17 and had a diagnosis of UC. They were randomly assigned to receive multimatrix mesalamine 30, 60, or 100 mg/kg once daily for seven days. The pharmacokineti
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *